MedPage Today on MSN6d
Tezspire Treats Chronic Sinus Symptoms With Nasal PolypsTezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...
Amgen and AstraZeneca have announced full results from the Phase III, registrational WAYPOINT trial showing that Tezspire ...
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation ...
Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...
The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...
5d
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback